Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Weighted Average) (2023 - 2025)

Historic Shares Outstanding (Weighted Average) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $82.4 million.

  • Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) rose 47.08% to $82.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 47.08%. This contributed to the annual value of $73.9 million for FY2024, which is 4380.23% up from last year.
  • Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) amounted to $82.4 million in Q3 2025, which was up 47.08% from $82.2 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) peaked at $82.4 million during Q3 2025, and registered a low of $49.3 million during Q1 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $71.2 million (2024), whereas its average is $66.7 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 6463.28% in 2024, then skyrocketed by 47.08% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) stood at $51.4 million in 2023, then skyrocketed by 43.8% to $73.9 million in 2024, then increased by 11.48% to $82.4 million in 2025.
  • Its last three reported values are $82.4 million in Q3 2025, $82.2 million for Q2 2025, and $82.1 million during Q1 2025.